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Glioblastoma  multiforme  (GBM)  patients  have  a poor  prognosis.  After  tumor  recurrence  statistics  suggest
an  imminent  death  within  1–4.5 months.  Supportive  preclinical  data,  from  a  rat  model,  provided  the
rational  for  a prototype  clinical  vaccine  preparation,  named  Gliovac  (or  ERC  1671)  composed  of autologous
antigens,  derived  from  the  patient’s  surgically  removed  tumor  tissue,  which  is  administered  together  with
allogeneic  antigens  from  glioma  tissue  resected  from  other  GBM  patients.  We  now  report  the ﬁrst  results
of  the  Gliovac  treatment  for  treatment-resistant  GBM  patients.
Nine (9)  recurrent  GBM  patients,  after  standard  of  care  treatment,  including  surgery  radio-  and
chemotherapy  temozolomide,  and for  US patients,  also  bevacizumab  (AvastinTM), were  treated  under  a
compassionate  use/hospital  exemption  protocol.  Gliovac  was  given  intradermally,  together  with  human
GM-CSF  (Leukine®),  and  preceded  by  a regimen  of  regulatory  T cell-depleting,  low-dose  cyclophos-
phamide.
Gliovac  administration  in  patients  that  have  failed  standard  of  care  therapies  showed  minimal  toxicity
and  enhanced  overall  survival  (OS).  Six-month  (26 weeks)  survival  for  the  nine  Gliovac  patients  was 100%
versus  33%  in  control  group.  At  week  40,  the  published  overall  survival  was  10%  if  recurrent,  reoperated
patients  were  not  treated.  In  the Gliovac  treated  group,  the survival  at 40 weeks  was  77%.  Our  data
suggest  that  Gliovac  has  low  toxicity  and  a promising  efﬁcacy.  A  phase  II  trial  has  recently  been  initiated
in  recurrent,  bevacizumab  naïve  GBM  patients  (NCT01903330).
ublis©  2015  The  Authors.  P
. IntroductionActive immunotherapy against cancer represents an excit-
ng treatment option, involving the stimulation of the patient’s
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immune system against tumor antigens. However, therapeutic
immunization against the most malignant brain tumor – glioblas-
toma multiforme (GBM) – is a formidable challenge. Although,
brain parenchyma inﬁltrating CD8-positive T cells have been
detected in these brain tumors [1,2] and even anecdotal rejection of
gliomas following bacterial infection was reported [3], GBM,  once
established, normally evades immune detection. This is a result of
decreased MHC  antigen expression and active suppression of local
and systemic immune reactions [4]. Apart from tumor-mediated
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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mmune suppression the patient’s immune reactivity is further
uppressed by both high doses of iatrogenic chemotherapy [5] and
orticosteroid treatment. All these factors tend to tilt the balance
oward an immune suppressive state [6], as evidenced by signiﬁ-
ant leucopenia, a decrease in total CD4+ T cells and a functional
ncrease in regulatory T cells.
Glioblastoma mutiforme (GBM) is the most common and most
ggressive malignant brain tumor, with a very poor prognosis
ue to marginally effective standard therapy, involving tumor-
ebulking surgery, followed by radiotherapy and chemotherapy.
his cancer is very difﬁcult to treat and most patients die after
umor recurrence within 12–16 months [7,8]. At the time of
umor recurrence, statistics suggest an imminent death with
n average overall survival (OS) of 1–4.5 months [8], depend-
ng on the size of the tumor, the Karnofsky performance score
KPS) score, and the tumor localization. In the USA, bevacizumab
Avastin®), a blood vessel growth-inhibiting, anti-angiogenic anti-
ody, is administered as second line of treatment [9], but is not
pproved by EU authorities. Once the tumor recurs on beva-
izumab treatment it is universally fatal with survival times of
ess than a few weeks [8]. Consequently, novel therapies are highly
emanded.
Successful post-operative immunotherapy enabling immune
ecognition and destruction of residual or recurrent tumor cells
ould provide an enormous clinical value. Induction of a vaccine-
nduced immune response by adaptive immune lymphocytes
nitially requires efﬁcient presentation, by antigen presenting
ells, of tumor associated antigens (TAA) (referred to as signal 1)
ogether with co-stimulatory signals (called signal 2). Most TAAs
re inherently, poorly antigens and require an adjuvant to break
mmunological tolerance following proper of induction immune
ignal 2 [10]. Here we used recombinant granulocyte–macrophage
olony stimulating factor (GM-CSF) as an immunological adju-
ant, which is able to facilitate both signals 1 and 2 in different
ypes of cancer vaccines [11]. GM-CSF supports dendritic cell (DC)
ecruitment and development; hence enabling antigen uptake
nd increasing antigen presentation. In addition, GM-CSF stimu-
ates DC maturation, characterized by expression of co-stimulatory
olecules (signal 2), facilitating antigen-presentation for T cells12]. This cytokine is commonly used to generate DCs for the use
n DC cancer vaccines [13]. GM-CSF’s safe pharmacological use in
atients is well-established, which makes it attractive and feasible
or clinical use in general.
ig. 1. Time line of Gliovac treatment administration. The tumor resection is considered a
he  patient receives low-dose cyclophosphamide (Cy) for three consecutive doses (day 10
uch  as regulatory T cells [14]. The ﬁrst immunization with an allogeneic tumor antigen
mmunizations, given at a 3–4 day intervals, consist of the patient-derived autologous an
reparation – all in combination with GM-CSF. The patient is left in rest for 1 week and a n
38  followed by immunization Gliovac treatment. This treatment has been repeated for s 33 (2015) 2690–2696 2691
Preclinical efﬁcacy of this immunotherapy approach in an
immunocompetent Lewis rat CNS-1 glioma model supported the
implementation of this treatment concept in compassionate use
for recurrent GBM patients. Here we  describe our ﬁrst clinical data
for patients with a KPS score above 60, using this novel immuniza-
tion approach, consisting of a combined administration of multiple
allogeneic and autologous tumor-isolated antigens.
2. Materials and methods
2.1. Treatment scheme
The Gliovac treatment is composed of six cycles of ﬁve intra-
dermally administrated treatment doses (Fig. 1). Every dose is
composed of both a cellular component and a lysate component,
prepared from freshly, surgically removed, GBM tumor tissue, and
stored in separate vials.
The cell vial contains 250 l of a suspension of 1 × 105–1 × 106
irradiated DNFB-modiﬁed tumor cells, and the lysate vial contains
250 l of the equivalent of a lysate of 1 × 105–1 × 106 irradiated
DNFB-modiﬁed tumor cells. In the schedule (Fig. 1) the allogenic
Gliovac A, B, and C product doses are prepared from three differ-
ent glioblastoma tumor donors, while autologous Gliovac D dose is
derived from the patient’s tumor.
Gliovac treatment is administered together with GM-CSF
(Leukine®) as adjuvant following the oral administration of a low
dose of cyclophosphamide for 3 days (Endoxan®). The treatment
scheme of two cycles is depicted in Fig. 1. The six treatment cycles
were repeated every 28 days.
2.2. Vaccine production
The Gliovac product has been manufactured, under GMP
approved aseptic conditions, from surgically removed GBM tissues.
The tumor tissues were received and released by a tissue bank
of human body material, after testing for absence of viral infec-
tions, including HIV, HBC, HCV, CMV, HTLV, and also Syphilis. After
coding by a suitable anonymization procedure, they were sent in
temperature-controlled conditions, to the GMP  manufacturing site,
immediately after the surgery. The cells were isolated by mechan-
ical dissection and washed in Earl’s balanced salt solution (EBSS)
medium. Isolated cells were counted and haptenized with 1-ﬂuoro
2,4-dinitroﬂuorobenzene (DNFB), to improve immunogenicity. The
s day 0 (D0). The Gliovac is administered in repeated cycles. Ten days after surgery,
–12: D10–D12; purple arrows) in order to reduce immune inhibitory immune cells,
-preparation, in conjunction with GM-CSF, is given on day 15 (D15). Subsequent
tigens, two distinct allogeneic antigen-preparations, and a ﬁnal autologous antigen
ew cycle (cycle 2) restart with cyclophosphamide for three consecutive doses from
ix cycles.
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otal amount of haptinized cells was collected and divided in two
qual parts. One part of cells was preserved for freezing in a sucrose
edium, one part was lysed by osmotic shock. Both, the solutions
f the cells and the lysates were irradiated with 25 Gray of gamma
adiation to make the cells replication incompetent as a result of
NA damage. All preparations were stored at −80 ◦C.
.3. Patient characteristics
Eligible adult patients, with histologically conﬁrmed WHO  grade
V malignant glioma and documented treatment failure to standard
f care treatment (SOC), including surgery followed by concomi-
ant chemotherapy plus radiotherapy with TMZ, and bevacizumab
AvastinTM) in second line of treatment for one of them. All the
atients presented a relapse of glioblastoma. Included patients are
atients with an operable tumor mass since the treatment is com-
osed, in part, of autologous tumor cells and lysates. Patient surgery
as generally limited by the localization of the tumor (≤95% of the
otal tumor mass). Primary end points collected for each individ-
al patient were toxicity, while secondary end points were median
verall survival (OS) and radiographic responses. A total of nine (9)
atients, presenting a KPS score of >60, enrolled, four on a phase
/I protocol at the Cliniques of South Luxembourg-Belgium, one
n compassionate/single patient IND protocol at UC Irvine Medical
enter, one from Vilnius Hospital (Lithuania), one from the Uni-
ersity Hospital Saarland, Homburg (Germany), and two from the
oundation Center for Epilepsy and neurological Diseases (FIRE)
Colombia). Median age was 48 years, with ﬁve female and four
ale patients. The average KPS was 80 (60–100). In Europe, treat-
ents were performed in accordance with the ethical standards
aid down in the 1964 Declaration of Helsinki and its later amend-
ents. US patients were treated under IRB-approved protocols.
ll patients (or their guardians; if applicable) signed an informed
onsent form prior to their inclusion, and each treatment was
pproved by the hospital’s ethical committee. Patient demograph-
cs are shown in Table 1.
.4. Immunomodulators and potentiators
Cyclophosphamide (CY; CalBiochem, 239785) was given at
0 mg/dose.
Human-GM-CSF (Leukine®) was purchased as an Escherichia coli
xpression product from Bayer HealthCare Pharmaceuticals (Seat-
le, WA,  USA), and administered intradermally, with the vaccine, at
00 g/dose diluted in 500 l of water for injection (WFI).
.5. Statistics
For software for the statistical analysis of the patient data was
raphPad Prism 5.03 for Windows. Median Overall-survival (OS-
ime between recurrence and death) was determined. The impact
n OS of the treatment received (with or without GLIOVAC) was
nalyzed. For the univariate analysis of potential prognostic fac-
ors, time-to-event distributions of the patients were constructed
sing Kaplan–Meier plots and P values were obtained using log-
ank tests. Signiﬁcance was set at P < 0.05.
. Results
.1. Rat model
In a syngeneic, immunocompetent Lewis rat CNS-1 model we
oted complete tumor regression (six out of six animals) only
n the group of animals that received the vaccine (antigens from
yngeneic and allogeneic cells) in conjunction with GM-CSF and
yclophosphamide (CY) pre-treatment (data not shown). In the 33 (2015) 2690–2696
control groups, some delay in measurable tumor growth was
observed, relative to the untreated control groups (zero out of six
animals showed tumor growth reduction). In the control groups,
receiving CY only (tumor growth delay was noted in three out of
six animals), in the CY plus GM-CSF group (one out of six animals
showed tumor growth delay), while in the CY plus vaccine group
three out of six animals showed growth delay.
3.2. Clinical ﬁndings
GBM patients have a very poor prognosis. Upon relapse, the
overall survival depends of a multitude of factors, however, major-
ity of the patients face imminent death after 1–4.5 months at best
[8].
Encouraging ﬁndings in the preclinical rat model provided
the rational and scientiﬁc basis to investigate the safety and
efﬁcacy of this immunotherapeutic concept, named Gliovac (or
ERC1671), in individual GBM relapsing patients, with no remaining
treatment options, under compassionate use/hospital exemption
conditions. Gliovac is an immunotherapy based on (allo)immune
response triggering following non-syngeneic tumor antigen (cells
and lysates) injection/transplantation, reﬂecting the preclinical
approach described in CNS-1 Lewis rats. During each immuniza-
tion cycle, the immune effector response is triggered by breaking
tolerance to the patient’s tumor antigens upon administration
of allogeneic (non-self) DNFP-modiﬁed tumor antigens, at the
ﬁrst injection (Gliovac A), and subsequent focusing of the trig-
gered immune reaction toward the patient’s tumor antigens,
upon administration of patient-derived autologous tumor antigens
(Gliovac D) (Fig. 1). This is followed by two  additional (booster)
injections of allogeneic antigen preparations (Gliovac B and C) and
a ﬁnal injection of Gliovac D. The immunizations are preceded by
a short regimen of low-dose, metronomic cyclophosphamide (CY)
[14], which depletes immune inhibitory immune cells. Each immu-
nization with tumor antigens is accompanied by a co-injection of
GM-CSF [11,12].
3.2.1. Patient selection
From January 2012 to July 2014, nine adult patients with recur-
rent glioblastoma were treated under Institutional review board
(IRB)-approved protocols at the Clinique du Sud Luxembourg,
Arlon, Belgium, University of California, Irvine, CA, USA, Univer-
sitäts Klinikum Homburg, UKS, Germany, from Vilnius Hospital
(Lithuania) and the Foundation Center for Epilepsy and Neurolog-
ical Diseases (FIRE) (Colombia). All these patients were previously
treated with standard care, including surgery followed by con-
comitant radiotherapy and chemotherapy with TMZ, and for US
patient, bevacizumab (AvastinTM) as a second line of treatment. All
the patients presented with recurrent, treatment resistant tumors.
Only patients with an operable tumor mass were included in this
protocol, since the treatment is composed, in part, of autologous
tumor cells and lysates. Patient surgery, however, was generally
limited due to the localization of the tumor (≤ 95% of the total
tumor mass).
Primary data collected were toxicity, while secondary endpoints
were median overall survival (OS) and radiographic response.
3.2.2. Clinical safety
The most common toxicities observed were mild and tran-
sient: two out of nine patients developed grade 2 headaches,
and four showed grade 2 local erythema at the injection site.
The local skin reactions (induration, erythema and ulceration) are
not surprising for a local immune reaction following intrader-
mal  administration [15]. In fact, these local reactions indicate the
development of immune responses. The diameters of the observed
erythema’s were between 1 and 3 cm,  which however, were not
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Table  1
Patient information. For each patient are indicated: age (gender), HLA (autologous), HLA of allogeneic donors (in bold overlapping HLA), number of cycles, efﬁcacy of the
treatment in terms of changes in tumor mass, if dead on week 40, toxicity observed (ERY, local erythema; HA, headache; NA, not applicable), overall survival (OS) from the
relapse  detection. UN, unavailable.
Patient
number
Age
(gender)
HLA
autologous
Known HLA
allogeneic received
Cycles
received
Efﬁcacy Dead Toxicity
observed
OS from
relapse
1 61 (F) A 02/03 A
1/2/3/24/26/32/33
5 cycles Tumor
regression
Yes ERY 28 w
B  15/44 B 7/8/18/35/37/40/
44/50/51
Stable 17 wk
C  03/05 C 2/3/6/7 4 cycles Stable 28 wk ERY + HA >40 w
2  65 (M)  A 11/26 A 1/2/3/24/32/33 4 cycles Stable ERY + HA >40 w
B  44/52 B
7/8/15/18/35/37/40/44
C 14/12 C 2/3/4/5/6/7/12
3  47 (M)  UN A 2/24/26/32/33
B
7/35/37/40/44/50/51
C  2/3/4/6/7
4  64 (F) A 25/31 A 1/2/3/11/24/26 5 cycles Stable 30 wk ERY >40 w
B  18/51 B 7/8/13/15/18/35/
37/40/44/52
C  04/12 C
2/3/4/5/6/7/12/14
5 50 (F) UN A
1/2/3/11/24/26/30
3 cycles Stable 26 wk Yes NA 35 w
B
8/13/15/18/35/44/52
Disease
progression
C  3/4/5/6/7/12/14
6  52 (M)  UN A 1/2/11/24 6 cycles Tumor
regression
NA >40 w
B  8/13/18/35/44
C  4/5/6/7
7  57 (F) A 03/68 A 1/2/3/11/24 6 cycles Stable ERY >40 w
B  27/35 B 8/13/15/18/35/44
C  04/07 C 3/4/5/6/7/
8 28 (M)  A 02/24 A
1/2/3/11/26/29/30/68
6 cycles Stable NA >40 w
B  07/49 B
7/8/13/27/35/44/51/52
C 07/– C 4/6/7/12/14/16
9  27 (F) A 23/24 A 3/11/26/29/30/68 6 cycles Stable NA >40 w
o
c
o
a
i
o
3
o
–
o
w
d
5
MB  35/– B
7/13/27/35/44/51/52
C 04/– C 4/6/7/12/14/16
bserved in all patients. Hence, no clear correlation between efﬁ-
acy and erythema response can be concluded (as yet). Also, other
bserved mild systemic reactions, including self-limiting fever
nd chills, represent expected outcomes related to the intended
mmune stimulation [16]. The treatment did not trigger other seri-
us adverse events.
.2.3. Clinical efﬁcacy – Radiology data
Magnetic resonance imaging (MRI) of the brain with and with-
ut contrast was used to evaluate the tumor response to treatment
 using the RANO criteria [17]. Signiﬁcant responses were seen
n imaging – which, suggest that Gliovac/ERC1671 shows efﬁcacy
ithin our clinical settings, as illustrated for two  patients in more
etail in the case report (Box 1 supplementary info), visible in Figs.
A–C and 6, online only. Clear imaging results were also noted in the
RIs of most other patients (Figs. 2, 3, and 6). One patient showedmultifocal GBM, with multiple tumors (Fig. 2, left panel), which
all showed remarkable reduction after one treatment cycle (Fig. 2,
right panel). Another patient showed a noteworthy reduction in
tumor load, visible at the end of cycle 1 (Fig. 3, left panel), after the
second treatment period (Fig. 3, right panel).
All the patients with a KPS of >60, when treated with Gliovac,
responded to the treatment by a stabilization of the tumor, and,
at 40 weeks post recurrence a prolongation of survival for about
30 weeks (at 77% survival) was  observed versus historic untreated
control patients (10 weeks).
3.2.4. Clinical efﬁcacy – Overall survival
Of the nine patients, all had complete follow-up (until week
40). Patients’ mean age was 48 (range from 27 to 63) years.
The mean Karnofsky performance score (KPS) 1 week after the
surgery at the time of recurrence was  80 (range from 60 to
2694 V.E.J.C. Schijns et al. / Vaccine 33 (2015) 2690–2696
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sig. 2. MRI scans of a patient made on 31 May 2012 (left, pretreatment), versus Jun
rrows  indicate the locations of tumor tissue contrast staining.
00). Our data were compared to the published survival data of
eoperated, untreated (KPS >60) patients receiving standard care
18].The rates of overall survival (OS) achieved by Gliovac/ERC1671
reatment are signiﬁcantly increased (p = 0.0001), relative to those
eported historically for patients after surgery for recurrent GBM
n a recent retrospective analysis published by Barker et al. [18]
ig. 3. MRI  scans of a patient made on February 12, 2013 (left) versus April 04, 2013 (r
agittal view [bottom]).2012 (right) following one treatment cycle (MRI scan, coronal view; end 1st cycle).
(Fig. 4). Fig. 4 shows the comparison between Gliovac treated
patients (n = 9; solid line) and control patients (n = 39; dashed line),
both with KPS scores ranging between 60–100. Data were recorded
until week 40 after reoperation. Six-month (26 weeks) survival for
the nine Gliovac patients was  100% versus 33% in control group. At
week 40, the published overall survival was 10% if patients were
not treated. In the Gliovac treated group, the survival at 40 weeks
ight), following one additional treatment cycle (MRI scan, coronal [top] view and
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Fig. 4. Overall survival of patients treated with Gliovac (n = 9; solid line) versus
o
a
w
o
G
(
v
a
t
s
b
p
b
t
T
d
i
i
l
m
f
e
t
a
n
3
t
m
r
g
i
b
i
n
t
4
i
r
p
p
r
function of both peripheral blood regulatory T cells and interferon-verall survival of published control patients (dashed line). Data of control patients
re extracted from Fig. 3A of the publication [18].
as 77%. The statistic analysis clearly indicates a signiﬁcant effect
f Gliovac on the survival of recurrent patient (p < 0.0001).
All patients with a KPS score between 60 and 100, treated with
liovac/ERC 1671 were still alive at week 28 (about 7 months)
Fig. 4, solid line). One patient showed after three cycles of
accination complete tumor regression, which was  observed after
n average of 8 (4–12) weeks. It should be noted that for most of
he recurrent Gliovac/ERC1671 patients included in this report the
urgery achieved only limited, subtotal resection, due to the vital
rain area and critical location of the tumor, which is a negative
rognostic factor relative to complete resection [19].
For one patient, further histological analysis of residual tumor
iopsies showed that the Gliovac treatment corresponds with inﬁl-
ration of activated macrophages (CD68-positive), CD4+ and CD8+
 cells, and strongly reduced viable tumor growth (Ki67 staining;
ata not shown) [20]. These observations sustain the efﬁcacy of
mmune effector response-induction and local immune inﬁltration
n the tumor bed.
Those ﬁrst results in man  are highly encouraging, despite the
ate stage of disease, the resistance to standard therapeutic treat-
ent, and the incomplete tumor resection by surgery. However,
uture clinical trials require strict selection criteria, limiting the
xtent of disease to patients who do not have multifocal or lep-
omeningeal disease [8,21]. Potential improvements should also
ddress the timing of Gliovac administration after the initial diag-
osis, e.g., treatment before immunosuppressive chemotherapy.
.3. Conclusive interpretation of clinical results
Current data suggest that even in advanced stages of disease,
he Gliovac treatment increases overall survival of recurrent, treat-
ent resistant GBM patients. These encouraging clinical case study
esults, from relapsing GBM patients in a compassionate use pro-
ram, provided support to FDA authorities (FDA) to approve the
nvestigation of the product in a phase II, randomized, double
linded clinical trial, comparing the product’s safety and efﬁcacy
n combination with bevacizumab with bevacizumab in combi-
ation with placebo treatment in GBM patients who have failed
emozolomide.
. Discussion
The present study shows that Gliovac (or ERC 1671)
mmunotherapy is safe and potentially effective in treatment-
esistant GBM patients. At 40 weeks post recurrence this approach
rolonged the observed 77% survival among relapsing glioblastoma
atients with an increase in survival of about 5-month (30 weeks)
elative to historic controls (10 weeks) [18]. 33 (2015) 2690–2696 2695
Our clinical protocol has been designed based on supportive
proof-of-concept data observed in a CNS-1 glioma model in Lewis
rats. In the rat model we observed tumor regression, visible as
a reduction in tumor growth rate after about 2 weeks of initia-
tion of immunotherapy, using allogenic and syngeneic antigens
from glioma cell lines, when administered together with GM-CSF
as immunological adjuvant, eventually resulting in non-detectable
tumor volumes. This anti-tumor response resulted in immunolog-
ical memory, since the majority of animals that controlled the ﬁrst
tumor, also rejected a secondary tumor without noticeable tumor
growth. All animals were pretreated with a low-dose CY in order
to deplete the immunosuppressive regulatory T cells [22].
The rationale of the Gliovac prototype vaccine is to evoke oligo-
clonal, partly allo-speciﬁc, immune induction, using a broad set
of tumor antigens, derived from freshly resected whole tumor tis-
sue. This will reduce the chance of immune escape, which is more
likely to occur when using a single-antigen-targeted immunother-
apy. The vaccine is composed of autologous antigens, derived from
the patient’s surgically removed tumor tissue, which is adminis-
tered in conjunction with antigens from glioma tumor tissue that
was surgically removed from allogenic donor patients. This allo-
genic tumor material provides an additional source of antigens
that can be stored in a tissue bank for “off-the shelf” use. The allo-
genic TAAs may  display partial HLA-matching with the patient. The
mismatching HLA molecules serve to trigger and enhance an allo-
immune response. In this ﬁrst in man  study, partial HLA mismatch
information is available (Table 1), but the role of HLA mismatches
in effectiveness will have to be evaluated in a stringent clinical
trial currently ongoing (NCT01903330). Relevant unique or shared
TAAs overexpressed by tumor cells are present among thousands
of irrelevant immunotolerant non-tumor associated antigens. A
multivalent vaccine will prevent or minimize escape of residual
tumor cells, due to antigenic loss, or active MHC  down-regulation.
In addition, a tumor antigen mixture is preferred above monova-
lent synthetic peptides, because of their restricted use in patients
with deﬁned HLA types only.
We used GM-CSF as an immune adjuvant, which is known to
augment immune responses against protein of peptide based vac-
cines [23], as well as to tumor cell vaccines genetically engineered
to secrete GM-CSF [24]. This cytokine has been used as a hematopoi-
etic growth factor in patients undergoing chemotherapy, and is
well-tolerated [25]. When administered in the skin it recruits and
activates antigen-presenting cells, including epidermal Langerhans
cells [26] Moreover, GM-CSF showed positive effects relative to
other cytokines, in preclinical rat and mouse glioma vaccine studies
[27,28].
Immunological protection against gliomas has been ascribed to
cell-mediated immune reactions involving cytolytic CD8+ T lym-
phocytes [29]. Depletion of these cells has demonstrated their
critical role in vaccine-mediated antitumor immunity [30]. These
observations are in line with the histological results from sequen-
tially taken tumor autopsy specimens. Biopsy specimens of a
Gliovac treated patient showed local immune inﬁltration in the
tumor bed, consisting of abundant activated macrophages (CD68),
as well as CD4 and CD8 T cells. This immunohistological stain-
ing was  associated with a strongly reduced viable tumor growth
index, as evidenced by reduced Ki67 positive cells [20]. Although,
in general, tumor-speciﬁc immune response monitoring and a clear
relationship with clinical outcome has proven difﬁcult for tumor
vaccines, it will be of interest to investigate in detail the contribu-
tion of particular lymphocyte populations to protective antitumor
efﬁcacy of Gliovac – for example, by monitoring of the number and-producing CD8 T cells speciﬁc for prototype glioma antigens.
Clinical studies using cell-based vaccination, employing a broad
set of tumor antigens, have been carried out before. Some used
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utologous cells, e.g., M-vax [31], or allogeneic cells, e.g., Canvaxin
32], or autologous lysates, e.g., oxidized tumor cell lysate (OC-L), or
llogeneic lysates, such as Melacine [33]. Although safe, in phase I
nd II clinical trials, these products failed to provide convincing sta-
istical evidence of positive immunological and clinical outcome.
he innovative aspect of the Gliovac is to combine all elements
autologous and allogeneic, cells and lysates) in order to trigger
trong polyclonal immune reactions. Autologous components con-
ain patient-speciﬁc antigen, while allogeneic components are able
o induce an allo-immune reaction. This strategy enables trigg-
ring of an immune response against a broad array of tumor
ntigens, including tolerance breaking allo-immune reactivity, -a
lassical allograft-directed immune response-, typical for non-
atching major histocompatibility between the injected graft cells
nd antigens and the host. The allogenic part of the Gliovac treat-
ent contains antigens from GBM tumors from allogeneic donor
atients, that overlap with speciﬁc tumor antigens in the patient.
The observed safety and promising clinical results of Gliovac in
he compassionate use program, lead the US authorities (FDA) to
pprove the development of a phase II clinical trial registered under
umber (NCT01903330), which is currently enrolling patients.
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